Lilly clinically tests antibody against COVID-19 variants

Drug maker Eli Lilly is testing a SARS-CoV-2 antibody designed to work against all variants of COVID-19 currently known to be circulating. The clinical trials are part of Lilly’s BLAZE-4 study in patients with mild-to-moderate COVID-19 illness. The FDA recently revoked emergency authorization of Lilly’s first COVID-19 antibody, bamlanivimab, because research indicated antibodies delivered as monotherapies are less effective against variants of SARS-CoV-2. (Fierce Biotech article, 5/4/21)